



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

September 19, 2023

Wei-Wu He  
Chief Executive Officer  
CASI Pharmaceuticals, Inc.  
1701-1702, China Central Office Tower 1  
No. 81 Jianguo Road Chaoyang District  
Beijing, 100025  
People's Republic of China

**Re: CASI Pharmaceuticals, Inc.**  
**Form 20-F for the Fiscal Year December 31, 2022**  
**File No. 001-41666**

Dear Wei-Wu He:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Disclosure Review Program

cc: Peter Huang